title: Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer.
abstract: OBJECTIVE
  The optimal concurrent chemoradiotherapy regimen for definitive treatment of locoregionally advanced head and neck cancer remains to be determined. The present investigation reports toxicities, disease control, patterns of failure, and survival outcomes in a large mature cohort of patients treated with low-dose weekly platinum-based concurrent chemoradiotherapy.
  
  
  METHODS
  Retrospective single-institution series.
  
  
  METHODS
  Toxicity and outcome data for locoregionally advanced head and neck cancer patients treated with low-dose weekly platinum-based chemotherapy concurrent with standard fractionation radiotherapy were retrospectively collected and analyzed from a clinical database. Survival analysis methods, including Kaplan-Meier estimation and competing risks analysis, were used to assess locoregional disease control, freedom from failure, and overall survival.
  
  
  RESULTS
  Ninety-six patients were eligible for the present analysis. Nearly all patients had American Joint Committee on Cancer clinical stage III to IVB disease (99%). Severe acute toxicities included grade 3 mucositis (61%), grade 3/4 nausea (27%/1%), and grade 3 neutropenia (8%). Thirty-seven patients (38%) required hospitalization for a median of 7 days (range, 1-121). Ninety-two percent of patients completed the fully prescribed course of radiotherapy, and 87% completed >or=6 cycles of chemotherapy. At a median survivor follow-up of 40 months (range, 8-68), 47% of patients were without evidence of disease recurrence. The estimated 4-year freedom from failure and overall survival were 48% and 58%, respectively. Initial site(s) of disease failure were locoregional for 22 patients, locoregional and distant (five patients), and distant only (14 patients).
  
  
  CONCLUSIONS
  Weekly low-dose platinum-based chemotherapy with full-dose daily radiotherapy is a tolerable alternative regimen for locoregionally advanced head and neck cancers, with comparable efficacy and patterns of failure to alternative regimens.
authors: Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina 29414, USA.
authors: John M
authors: JM
authors: Watkins
authors: A Jason
authors: AJ
authors: Zauls
authors: Amy H
authors: AH
authors: Wahlquist
authors: Keisuke
authors: K
authors: Shirai
authors: Elizabeth
authors: E
authors: Garrett-Mayer
authors: M Boyd
authors: MB
authors: Gillespie
authors: Terry A
authors: TA
authors: Day
authors: Anand K
authors: AK
authors: Sharma
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011832:Radiation Injuries; D015996:Survival Rate
chemical_list: D017239:Paclitaxel; D002945:Cisplatin